Our findings strongly advocate for CTGF inhibition as a novel adjuvant therapeutic strategy, particularly when paired with 5‐FU, for GC patients with a high prevalence of CAFs (Figure 7E). This evidence concerns the gene CCN2 and gastric cancer.